Prakash, S., Steers, N. J., Li, Y., Sanchez-Rodriguez, E., Verbitsky, M., Robbins, I., Simpson, J., Pathak, S., Raska, M., Reily, C., Ng, A., Liang, J., DeMaria, N., Katiraei, A., Stevens, K. O., Fischman, C., Shapiro, S., Kodali, S., McCutchan, J., … Gharavi, A. G. (2025). Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy. Journal of Clinical Investigation, 135(10). https://doi.org/10.1172/jci181164

Khan, A., Lim, T. Y., & Sanna-Cherchi, S. (2024). Mendelian Randomization Unveils Drug Targets for IgA Nephropathy. Journal of the American Society of Nephrology, 35(8), 988–991. https://doi.org/10.1681/asn.0000000000000434

Rehnberg, J., Segelmark, M., Ludvigsson, J. F., & Emilsson, L. (2024). Validation of IgA nephropathy diagnosis in the Swedish Renal Registry. BMC Nephrology, 25(1). https://doi.org/10.1186/s12882-024-03512-2

Rivedal, M., Mikkelsen, H., Marti, H.-P., Liu, L., Kiryluk, K., Knoop, T., Bjørneklett, R., Haaskjold, Y. L., Furriol, J., Leh, S., Paunas, F., Bábíčková, J., Scherer, A., Serre, C., Eikrem, O., & Strauss, P. (2024). Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy. Kidney International, 105(4), 717–730. https://doi.org/10.1016/j.kint.2023.12.010

Rajasekaran, A., Larkina, M., Julian, B. A., Canetta, P. A., Roehm, B. A., Khalid, M., Mariani, L. H., & Rizk, D. V. (2023). Optimal Conservative Therapy Use among Adult Cure Glomerulonephropathy Participants with IgA Nephropathy. Kidney360, 4(12), 1763–1769. https://doi.org/10.34067/kid.0000000000000306

Wooden, B., Tarragon, B., Navarro-Torres, M., & Bomback, A. S. (2023). Complement inhibitors for kidney disease. Nephrology Dialysis Transplantation, 38(Supplement_2), ii29–ii39. https://doi.org/10.1093/ndt/gfad079

Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, L. A., Lafayette, R., Maes, B., Małecki, R., Mercer, A., Noronha, I. L., Oh, S. W., … Zizzi, C. F. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. The Lancet, 402(10417), 2077–2090. https://doi.org/10.1016/s0140-6736(23)02302-4

Kiryluk, K., Freedberg, D. E., Radhakrishnan, J., Segall, L., Jacobson, J. S., Mathur, M., Mohan, S., & Neugut, A. I. (2023). Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review. Kidney360, 4(8), 1112–1122. https://doi.org/10.34067/kid.0000000000000165

Kiryluk, K., Sanchez-Rodriguez, E., Zhou, X.-J., Zanoni, F., Liu, L., Mladkova, N., Khan, A., Marasa, M., Zhang, J. Y., Balderes, O., Sanna-Cherchi, S., Bomback, A. S., Canetta, P. A., Appel, G. B., Radhakrishnan, J., Trimarchi, H., Sprangers, B., Cattran, D. C., Reich, H., … Gharavi, A. G. (2023). Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nature Genetics, 55(7), 1091–1105. https://doi.org/10.1038/s41588-023-01422-x

Liu, L., Khan, A., Sanchez-Rodriguez, E., Zanoni, F., Li, Y., Steers, N., Balderes, O., Zhang, J., Krithivasan, P., LeDesma, R. A., Fischman, C., Hebbring, S. J., Harley, J. B., Moncrieffe, H., Kottyan, L. C., Namjou-Khales, B., Walunas, T. L., Knevel, R., Raychaudhuri, S., … Kiryluk, K. (2022). Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-34456-6

Liang, K. V., Ellis, B. K., Stokes, M. B., Smith, R. J., Gu, X., & Gale, D. P. (2022). Hematuria and Proteinuria in a Patient With Recurrent Pulmonary Illnesses: A Quiz. American Journal of Kidney Diseases, 79(6), A13–A15. https://doi.org/10.1053/j.ajkd.2021.10.015

Marumoto, H., Tsuboi, N., D’Agati, V. D., Sasaki, T., Okabayashi, Y., Haruhara, K., Kanzaki, G., Koike, K., Shimizu, A., Kawamura, T., Rule, A. D., Bertram, J. F., & Yokoo, T. (2021). Total Nephron Number and Single-Nephron Parameters in Patients with IgA Nephropathy. Kidney360, 2(5), 828–841. https://doi.org/10.34067/kid.0006972020

Rehnberg, J., Ludvigsson, J. F., Carrero, J.-J., & Emilsson, L. (2021). Cancer risk in patients with immunoglobulin A nephropathy: a Swedish population-based cohort study. Nephrology Dialysis Transplantation, 37(4), 749–759. https://doi.org/10.1093/ndt/gfab322

Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., Jayne, D. R. W., Jha, V., Liew, A., Liu, Z.-H., Mejía-Vilet, J. M., Nester, C. M., Radhakrishnan, J., Rave, E. M., Reich, H. N., … Floege, J. (2021). Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100(4), 753–779. https://doi.org/10.1016/j.kint.2021.05.015